{"url_path":"/sec/tyra/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-220638-index.html","accession_number":"0001193125-26-220638","cik":"0001863127","ticker":"TYRA","issuer_name":"Tyra Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-220638-index.html","primary_entity_key":"0001863127","primary_entity_name":"Tyra Biosciences, Inc."},"word_count":78,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.\n\nDescription\n\n99.1\n\n[Press Release Issued on May 13, 2026](tyra-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nTYRA BIOSCIENCES, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nMay 13, 2026\n\nBy:\n\n/s/ Alan Fuhrman\n\n \n\n \n\n \n\nAlan Fuhrman\nChief Financial Officer"}